Biotech Values

[DewDiligence]

IDIX 2008-2009 Clinical Goals

[Updated based on guidance
from Canaccord Adams webcast.]


HIV

Mid 2008: Complete phase-1/2 IDX899 7-day monotherapy study using lower doses than 800mg. (Data from the 800mg cohort were reported on 2/6/08: #msg-26606685.) Report results at an unspecified medical conference in June.

3Q08: Start phase-2 IDX899 6-week combination study: IDX899+Truvada vs Sustiva+Truvada in first- and second-line patients.

End 2008: Partner IDX899 program following above phase-2 study.

Feb 2009: Report data from phase-2 combination study at CROI conference.


HCV

Mid 2008: File IND/CTA for IDX184.

End 2008: Report initial data for IDX184 in HCV patients. (The plan is to skip testing in healthy volunteers and proceed directly to patients.)

1H09: File IND/CTA for HCV protease inhibitor.